|
|
- LIBTAYO® (cemiplimab-rwlc) in Advanced NSCLC, BCC, CSCC High-Risk CSCC
LIBTAYO is a prescription medicine used to treat adults with a type of skin cancer called cutaneous squamous cell carcinoma (CSCC) to help prevent CSCC from coming back if your CSCC is at high risk of coming back after it has been removed by surgery and radiation
- Libtayo: Uses, Side Effects, Warnings - Drugs. com
Libtayo is a medicine used to treat skin cancer by working with your immune system Libtayo is used to treat a certain type of skin cancer called cutaneous squamous cell carcinoma (CSCC) that has spread to other parts of the body or cannot be treated with radiation or surgery
- LIBTAYO® (cemiplimab-rwlc) | Official HCP Website
LIBTAYO® (cemiplimab-rwlc) is a prescription medicine indicated for the treatment of adult patients with advanced NSCLC, CSCC, BCC, and as an adjuvant treatment for high-risk CSCC
- Cemiplimab - Wikipedia
Cemiplimab, sold under the brand name Libtayo, is a monoclonal antibody medication used for the treatment of squamous cell skin cancer [7][8] Cemiplimab belongs to a class of drugs that binds to the programmed death receptor-1 (PD-1), blocking the PD-1 PD-L1 pathway [6][9]
- LIBTAYO® Full Prescribing Information | Regeneron
LIBTAYO is indicated for the treatment of adult patients with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or curative radiation
- LIBTAYO (cemiplimab-rwlc) Label - Food and Drug Administration
LIBTAYO is a programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are
- Libtayo (cemiplimab-rwlc) - Uses, Side Effects, and More
Libtayo is a type of medicine known as immunotherapy This means that it can help your body’s own immune system work to fight against cancer Libtayo works by blocking a receptor called
- label - accessdata. fda. gov
LIBTAYO is indicated for the treatment of adult patients with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or
- LIBTAYO Full Prescribing Information
LIBTAYO is indicated for the treatment of patients with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or curative radiation
- What is LIBTAYO® (cemiplimab-rwlc) | Advanced CSCC
LIBTAYO is the first medicine approved by the Food and Drug Administration (FDA) to treat CSCC that has spread or cannot be cured by surgery or radiation LIBTAYO is a type of immunotherapy called a programmed death receptor-1 (PD-1) inhibitor
|
|
英文每年常用名排名
2024 年排名
2023 年排名
2022 年排名
2021 年排名
2020 年排名
2019 年排名
2018 年排名
2017 年排名
2016 年排名
2015 年排名
2014 年排名
2013 年排名
2012 年排名
2011 年排名
2010 年排名
2009 年排名
2008 年排名
2007 年排名
2006 年排名
2005 年排名
2004 年排名
2003 年排名
2002 年排名
2001 年排名
英文名字起源
希伯来
希腊
条顿
印度
拉丁
拉丁语
古英语
英格兰
阿拉伯
法国
盖尔
英语
匈牙利
凯尔特
西班牙
居尔特
非洲
美洲土著
挪威
德国
威尔士
斯拉夫民族
古德语
爱尔兰
波斯
古法语
盎格鲁撒克逊
意大利
盖尔语
未知
夏威夷
中古英语
梵语
苏格兰
俄罗斯
土耳其
捷克
希腊;拉丁
斯干那维亚
瑞典
波兰
乌干达
拉丁;条顿
巴斯克语
亚拉姆
亚美尼亚
斯拉夫语
斯堪地纳维亚
越南
荷兰
|